Loading stock data…
REPL
$9.24+0.27 (+3.01%)
After Hours$9.20-0.04 (-0.43%)· Last close Jun 9
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Replimune Group, Inc. in the Healthcare sector is trading at $9.18 with a market capitalization of $824M. Wall Street consensus targets $4.67 (6 analysts), implying a -49.1% move over the next 12 months. The stock is currently 31% below its 52-week high of $13.24, remaining 32.4% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -49.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.24
Potential Downside
0%
Whystock Fair Value$9.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$4.67-49.5%
Range$1.00 – $9.00
Fundamentals
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intend...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$824.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.55%
Volume
Today's trading volume
2.58M
Recent News
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
Why Is REPL Stock Gaining In Pre-Market Today?
Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.
How Replimune’s Drug Got Third Chance After White House Intervention
Company representatives met with officials in early May and by month’s end, the FDA was planning to review the melanoma medication again.
Stocks to Watch Recap: Dell, Gap, Costco, SentinelOne
↗️ Dell Technologies (DELL): Shares rocketed 33% after the technology company raised its full-year outlook and said first-quarter sales climbed 88% on demand for artificial intelligence products. Other computing stocks also jumped, including Hewlett Packard (HPE). ↘️ Gap (GAP): Shares dropped 15% after the clothing retailer cut its full-year revenue outlook and reported slowing sales for its Old Navy chain.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index decreasing 0.8% and